Refine
Document Type
- Article (2)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- PPARγ (1)
- Tin Organic Compounds (1)
- Trifluoromethyl Derivatives (1)
- metabolic syndrome (1)
- montelukast (1)
- polypharmacology (1)
- pranlukast (1)
- soluble epoxide hydrolase (1)
- zafirlukast (1)
Institute
- Biochemie und Chemie (1)
- Medizin (1)
- Pharmazie (1)
The title compound N,N-bis(trimethylstannyl)trifluoromethanesulfonamide (1) reacts with S2Cl2, SOCl2 and SO2Cl2 in a molar ratio 2:1 to yield the compounds S2Cl2 a twelve-membered ring 6. These are the largest neutral sulfur-nitrogen rings of coordination number two at the sulfur atoms known to date. 3 reacts with SOCI2 under migration of a methyl group from the tin to a sulfur atom to yield CF3SO2(R3Sn)NS(CH3)NSO2CF3 (7). 2,2,4,4-Tetramethyl-1,3-bis(trifluormethylsulfonyl)cyclodisilazan and 7 are formed by the reaction of 3 with R2SiCl2- The analogous four-membered germanium compound 8 is obtained from 1 and R2GeCl2. While the pyrolysis of 1 yields only the six-membered cyclotristannazan 9, the six-membered germanium analog is only formed in minor amounts. By treating 9 with R3SiCl the ring is decomposed to give 10. A six-membered ring is formed from the reaction of 1 with ClR2SiOSiR2Cl 11. The structure of 6 is discussed in detail. 6 crystallizes in the monoclinic space group C2/c with a = 24.408(5), b = 7.377(2), c = 16.715(3) Å, β = 117.16(3)° and Z = 4. It has a chair conformation which is different from the isoelectronic S12-structure.
Cysteinyl leukotriene receptor 1 antagonists (CysLT1RA) are frequently used as add-on medication for the treatment of asthma. Recently, these compounds have shown protective effects in cardiovascular diseases. This prompted us to investigate their influence on soluble epoxide hydrolase (sEH) and peroxisome proliferator activated receptor (PPAR) activities, two targets known to play an important role in CVD and the metabolic syndrome. Montelukast, pranlukast and zafirlukast inhibited human sEH with IC50 values of 1.9, 14.1, and 0.8 μM, respectively. In contrast, only montelukast and zafirlukast activated PPARγ in the reporter gene assay with EC50 values of 1.17 μM (21.9% max. activation) and 2.49 μM (148% max. activation), respectively. PPARα and δ were not affected by any of the compounds. The activation of PPARγ was further investigated in 3T3-L1 adipocytes. Analysis of lipid accumulation, mRNA and protein expression of target genes as well as PPARγ phosphorylation revealed that montelukast was not able to induce adipocyte differentiation. In contrast, zafirlukast triggered moderate lipid accumulation compared to rosiglitazone and upregulated PPARγ target genes. In addition, we found that montelukast and zafirlukast display antagonistic activities concerning recruitment of the PPARγ cofactor CBP upon ligand binding suggesting that both compounds act as PPARγ modulators. In addition, zafirlukast impaired the TNFα triggered phosphorylation of PPARγ2 on serine 273. Thus, zafirlukast is a novel dual sEH/PPARγ modulator representing an excellent starting point for the further development of this compound class.